Go to main content

Global Airway Research Clinic

​Type-2 inflammation represents a critical disease aspect of both upperand lower airways (Global Airways) and is the pathology behind the nasal polyposis, airway hyperresponsiveness, loss of smell, low quality of life and high burden of disease. In patients with Type-2 inflammation and severe uncontrolled CRSwNP (w/wo asthma), treatment with monoclonal antibodies seems to replace surgecal intervention and increase the need of research.

​Real-life treatment effect of biologic drugs in CRSwNP, Collection of clinical datas Nationwide in REDcap from both upper and lower airways, Combined treatment of surgey and biologic drugs versus biologic alone. Importance of pathology and inflammation, Importance of smell dysfunction, the neurological explantion, and the change during smell training. Cell growth in bench of nasal polyp tissue and invitro application of biologic drugs during growth, leading to information of the the in vitro differences between the different drugs. Sleep apnoe and DISE surgery, effect and posibilities.

Researchers 

  • Professor Vibeke Backer, MD DMSci, Pulmonologist, Rigshospitalet, UCPH and IKM​
  • Professor Christian von Buchwald, MD DMSci, ENT surgeon, Rigshospitalet, UCPH, IKM
  • Ass professor Kasper Aanæs, MD PhD, UCPH, IKM
  • Ass professor Eva K Kiaer, MD PhD, UCPH, MD

Phd Fellows 

Ditte G Mogensen Master nursing, Christiane Haase Master nursing, Anne-Sophie Homøe MD, Jens Tidemandsen MD, Christian K Pedersen MD

Associated department

Department of Pathology, Department of clinical physiology

Funding

CAG - Chr von Buchwald 

FEFFnonFESS - Vibeke Backer

​Visiting scientists ​

  • Professor Philippe Gevaert, Ghent, Belgium
  • Professor Peter Hellings, Leuven, Belgium
  • Professor Claus Bachert, Germany
  • Professor T Hummel, Dresden, Germany
  • Professor Peter Gibson, NewCastle, NSW Australia
  • Professor Ian Pavord, Oxford, UK

Projects​

  • FESSnonFESS: CRSwNP  surgery and biologics versus biologics
  • Tornado: CRSwNP - head to head of two difrent biologic drugs
  • Smell dysfunction in long COVID patients – RCT smell training versus placebo
  • Adrenal dysfunction in patients with CRS and asthma a study of adrenal insufficiency and osteoporose
  • Pulmonary dysfunction in patients with CRSwNP and possible change after treatment with biologic drugs.
  • Low level of physical activity in patients with CRSwNP and effect of biologic treatment



​​

Last updated:
Responsible editor
Klik for at scrolle op eller ned p� siden G� til toppen af siden